Remepy Appoints Eran Harary as Chief Medical Officer to Advance Hybrid Drug Pipeline

Remepy, the company pioneering Hybrid Drugs, has announced the appointment of Eran Harary, MD, as Chief Medical Officer. Harary joins the executive management team effective October 1, 2026, to advance the company's clinical development strategy and expand its Hybrid Drug pipeline.

Dr. Harary brings extensive experience in drug development, having previously served as Senior Vice President and Global Head of Specialty R&D at Teva Pharmaceuticals. In his new role, Harary will oversee the company's clinical development strategy, trial execution, and medical and regulatory engagement across its Hybrid Drug pipeline.

Harary's expertise spans the full drug development lifecycle, from early-stage research to late-stage clinical trials. He has contributed to numerous programs, including the development of UZEDY® (TV-46000), long-acting injectable programs, and promising therapies in movement disorders and immunology. His experience in shaping Teva's R&D strategy for AI, machine learning, and big data further enhances his value to Remepy.

The Hybrid Drug program, which combines prescription medicines with personalized, AI-driven therapeutic apps, is at the heart of Remepy's innovation. The company's lead program, Hybridopa for Parkinson's disease, has generated encouraging Phase IIa clinical results. These results are supported by peer-reviewed publications in Brain Communications and npj Parkinson's Disease, which describe the biological mechanisms underlying the Hybrid Drug clinical effect.

Hybrid Drugs integrate pharmacology with adaptive physical, cognitive, and behavioral interventions, delivering a single treatment through the standard prescription model. The Hybridopa program is set to commence its Phase III development in the fourth quarter of 2026, following strong Phase IIa results.

Remepy's approach to Hybrid Drugs is gaining traction, supported by emerging FDA frameworks for drug, software combination products. The company partners with leading pharmaceutical companies to bring these innovative treatments to market, enabling scalable, multidisciplinary care within a standard drug prescription model.

With Harary's leadership, Remepy is well-positioned to continue advancing its Hybrid Drug pipeline and bring this new class of medicine to patients. The company's commitment to patient-centered innovation and its pioneering approach to drug development make it a leader in the evolving landscape of pharmaceuticals.